FIELD: pharmaceuticals.
SUBSTANCE: group of inventions offers improved methods for preparing therapeutic compositions containing an antibody-drug conjugate ("ADC"), which reduce the variability of activity between different batches of ADC and enable the introduction of such therapeutic compositions in a narrow predetermined range of values. A method for reducing activity variability in an antibody-drug conjugate composition comprises steps of (a) determining a target drug concentration and (b) form an antibody-drug conjugate composition by varying the concentration of said drug in said composition to achieve a target concentration of the drug, thereby reducing variability of activity in said composition.
EFFECT: group of inventions provides minimizing the toxicity and increasing the effectiveness of the drug compositions.
25 cl, 11 dwg, 7 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF OBTAINING, PURIFICATION AND COMPOSING OF ANTIBODY-DRUG CONJUGATES | 2019 |
|
RU2801229C2 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| CONJUGATES OF ANTIBODY TO CCR7 AND DRUG | 2018 |
|
RU2777662C2 |
| ANTI-FOLR1 IMMUNOCONJUGATE APPLICATION SCHEMES | 2014 |
|
RU2801307C1 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2806049C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| MAITANZINOID DERIVATIVES WITH SELF-SPLITTING PEPTIDE LINKERS AND THEIR CONJUGATES | 2018 |
|
RU2765098C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
